Clinical trial
Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.
NCT00308243 · Emphycorp, Industry · Completed
Key facts
| NCT number | NCT00308243 |
|---|---|
| Title | Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis. |
| Official title | Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis. A Phase I, Double Blind, Placebo Controlled, Safety Study. Stage 1) |
| Lead sponsor | Emphycorp, Industry |
| Collaborators | Cellular Sciences, inc. Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis |
| Intervention type | Drug |
| Interventions | Sodium Pyruvate in 0.9% Sodium Chloride Solution |
| Enrollment | 15 |
| Start date | Mar 1, 2006 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Mar 29, 2006 |
| Last update posted | Jul 19, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: